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Strong correlation between the complement-mediated
antibody-dependent enhancement of HIV-1 infection
and plasma viral load
Judit Szabóa, Zoltán Prohászkab, Ferenc D. Tótha, Ágnes Gyurisc,
Judit Segesdic, Dénes Bánhegyid, Eszter Ujhelyie, János Minárovitsc
and George Füstb
Objective: We have previously demonstrated that complement-mediated antibody-
dependent enhancement (C-ADE) of HIV-1 infection correlates with accelerated
immunosuppression and disease progression in HIV-1-infected individuals. In the
present work the relationship between C-ADE and plasma HIV-1 RNA
concentrations was studied to determine the effect of C-ADE on viral replication.
Methods: Three studies were performed: (a) C-ADE and HIV-1 RNA concentrations
were determined in the serum and plasma aliquots taken at the same time from 98
HIV patients, mostly in the advanced stage of the disease; (b) the above two
parameters as well as HIV enzyme-linked immunosorbent assay (ELISA)-reactive
antibodies (Abbott HIV 1/2 test), and p24 antigen levels (Abbott antigen test; Abbott,
Delkenheim, Germany) were determined in four seroconversion panels purchased
from the Boston Biomedica firm; (c) changes of HIV-1 RNA concentration and 
C-ADE during a 17 month follow-up period were determined in 18 HIV-infected
patients. C-ADE was measured by the method previously established in our
laboratories. The results were expressed by an enhancement/neutralization index
(E/NI). HIV-1 RNA levels were determined with the Amplicor monitor kit (Roche,
Basel, Switzerland), and in some experiments with the nucleic acid sequence based
amplification (Organon Teknika, Turnhout, Belgium) kits.
Results: (a) We found a highly significant (P < 0.0001) positive correlation between
E/NI values reflecting the extent of HIV-1 infection enhancement and plasma HIV-1
RNA levels. Both E/NI and HIV-1 RNA levels negatively correlated to the CD4 cell
counts. (b) C-ADE was first detected just before, or concomitantly with,
seroconversion in 4/4 seroconversion panels. (c) Both E/NI values and HIV-1 RNA
levels significantly (P < 0.001) increased during a 17 month observation period in 18
HIV-infected patients.
Conclusion: We found strong association between the extent of the complement-
mediated antibody-dependent enhancement of HIV-1 infection and the plasma viral
load in HIV patients. On the basis of these findings, C-ADE correlates with HIV
replication in vivo, and potentially contributes to the progression of HIV disease.
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Introduction
At all stages of disease, HIV-1 RNA plasma levels, a
measure of the plasma viral load, remains the most
potent predictor of outcome in HIV-infected individu-
als [1–5]. Primary HIV infection is characterized by a
high titre viraemia; plasma HIV RNA concentrations
can exceed 106–107 copies/ml [6]. In concert with
seroconversion, initial symptoms resolve, viral load falls
precipitously by 2 or 3 logs, and follicular dendritic
cells (FDC) trap HIV as antigen-antibody-complement
complexes in the lymphoid tissue [7]. After fluctuating
for approximately 6 months, the plasma HIV RNA
level appears to stabilize at a steady state or ‘set-point’
[1].
The dominant host immunological factors involved in
the clearance of viraemia after its initial burst and fac-
tors that govern viral load during the later stages of
HIV disease have not been completely elucidated. The
relationship between humoral immune response, viral
load and progression to AIDS remains uncertain [8].
According to recent studies, the levels of both auto-
logous and heterologous neutralizing antibodies are low
or absent early in HIV infection without apparent cor-
relation to the decline in viraemia [9–12], although
some exceptions were reported [13,14]. Usually the
appearance of neutralizing antibodies is delayed 2–3
months when compared with the clearance of the acute
viraemic phase [12]. No convincing relationship
between neutralizing antibodies and containment of the
viral load in the chronic phase of HIV infection [15] or
association with long-term non-progression has been
noted [12,16].
By contrast, several recent data indicate that cytotoxic
T lymphocytes (CTL) contribute to the immunological
control of virus replication [11,17–19]. In addition to
the CTL response, CD8 T cell-mediated non-
cytotoxic suppression of HIV replication also signifi-
cantly contributes to the control of viraemia and disease
progression in adults and infants [20,21]. The vigorous
cell-mediated immune responses against HIV are thus
considered to be important in reducing viral load. The
continued presence of HIV in the plasma and lymph
nodes, however, shows that host immunity is incom-
plete. During clinical latency, HIV accumulates in the
lymphoid organs and replicates actively, a mechanism
responsible for the progressive disorganization and
destruction of secondary lymphoid organs, ultimately
resulting in the progression of disease. Presently, the
identification of the factors that lead to disease progres-
sion is a matter of debate.
Previous studies [22–25] demonstrated the presence of
enhancing antibodies (antibodies that facilitate HIV
infection in vitro) in the blood of HIV-infected individ-
uals. Two types of enhancing antibodies were
described: complement-independent, Fc-receptor
dependent [22], and complement-mediated antibodies
[23–25]. The HIV infection-facilitating effect of the
latter type of antibodies is mediated by the activation of
a plasma enzyme system, the complement system, and
mainly by complement receptor type 2 (CR2) on the
surface of target cells [25].
Some data confirm the clinical relevance of the
enhancing antibodies in HIV infection. Homsy et al.
[26] found the appearance of the Fc-receptor depen-
dent enhancing antibodies to be associated with the
progression of HIV disease. According to our previous
studies, complement-mediated antibody-dependent
enhancement (C-ADE) may also be of clinical impor-
tance. We have measured C-ADE with a markedly
higher frequency and in higher amounts in the sera of
patients with advanced stage HIV disease compared
with those in the sera of asymptomatic HIV-infected
persons [27]. These findings were recently confirmed
by McDougall et al. [28]. In a more recent study [29],
we have demonstrated the appearance of high-titre 
C-ADE to predict the rapid decline of the CD4 cell
counts and an increased probability of the development
of AIDS. In the same study, the lack of neutralization
measured in the presence of complement was also
found to be associated with a more rapid clinical pro-
gression of HIV disease, whereas no such association
was observed when the same measurement was per-
formed using heat-treated serum samples without the
addition of complement.
These findings prompted us to study the possible rela-
tionship between the titre of C-ADE and viral load,
the best predictive marker of HIV disease progression.
Materials and methods
Patients and sera
Ninety-eight patients [87 men, 11 women, 38 (range
10–68) years old] in advanced stages of HIV disease [58
patients in Centers for Disease Control and Prevention
(CDC) stage III or IVA, 40 patients in CDC stage IVB
or IVC] were enrolled in a cross-sectional study. The
average CD4 cell counts of the patients was 261 – 181
cells/µl (mean – SD), and the CD4 cell counts of 
80 out of 98 (82%) of the patients were below 
400 cells/µl.
A longitudinal study of C-ADE and viral load was 
performed in 18 patients in advanced stage HIV disease
untreated (n = 7), or treated with two different anti-
viral protocols (n = 11, zidovudine monotherapy: six,
zidovudine plus didanosine plus zalcitabine: five). The
patients were followed-up for a median of 17 (range
6–26) months. The baseline CD4 cell count of the
patients was 333 – 201 cells/µl.
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The appearance of enhancing antibodies shortly after
HIV infection was studied by using seroconversion
panels of Boston Biomedica Inc. (West Bridgewater,
MA, USA). Four panels (D, J, P, and Y) were 
purchased from the firm. Each seroconversion panel
consists of undiluted, frozen aliquots of plasma units
collected from a single donor. The samples do not 
contain preservatives. Before study, plasma samples
were recalcified, centrifuged and the supernatants were
heat treated (56oC, 30 min).
Cells and virus
HIV-1IIIB-producing H9 cells as well as MT-4 target
cells were maintained in RPMI 1640 medium contain-
ing 15% heat inactivated fetal calf serum and 50 µg
gentamicin/ml of cell culture medium. The virus titre
was determined by end-point dilution on H9 cells and
defined as the 50% tissue culture infective dose on
MT-4 cells (TCID50 value).
Measurement of enhancement/neutralization of
in-vitro HIV infection in the presence and
absence of complement
The assay was carried out as described previously [27].
Briefly, serum samples from the patients were heat-
treated (56oC, 30 min) and diluted at 1 : 64 in culture
medium in triplicate. One hundred microlitres of 
antibody dilutions were mixed with 100 µl of pooled
sera from HIV-seronegative healthy persons (normal
human serum; NHS). HIV-1IIIB (100 TCID50) in 
100 µl culture medium was added to 100 ml of anti-
body dilutions and incubated at 37°C for 1 h. The final
concentration of human complement in the samples
added to target cells was thus 1 : 4. In the case of each
patient’s serum, sample mixtures without complement
in which NHS was replaced by culture medium were
also tested. In each series of experiments, control cul-
tures infected with the virus alone were also estab-
lished. Then, 5 · 105 MT-4 cells in growth medium
were added and incubated in this medium without
change for 5 days at 37°C. The growth of HIV in the
cultures was monitored on each day by the reverse
transcriptase (RT) assay, as outlined by Hoffman et al.
[30]. Peak RT values were observed almost exclusively
at day 5. The results were measured as c.p.m. and
expressed finally by an index (enhancement/neutraliza-
tion index; E/NI) value. Index values were calculated
as follows: means of triplicate peak RT (c.p.m.) values
measured in cultures infected with the mixtures of
virus, patient’s serum (and NHS) at day 5 were divided
by the means of triplicate peak c.p.m. values measured
in control cultures infected with virus alone at day 5.
Samples with an E/NI of less than 0.5 (twofold
decrease in virus production) were considered as neu-
tralizing, whereas samples with an E/NI exceeding 2.0
(twofold increase in virus production) were considered
as enhancing. The variation coefficient of the method
was 7.23%.
Determination of CD4 cell counts
T cell subset determinations were performed by flow
cytometry (FACScan) by using the IMK lymphocyte
kit (Becton Dickinson, Mountain View, CA, USA).
Measurement of HIV-1 RNA level in the plasma
samples of the patients
In the cross-sectional study, plasma HIV-1 RNA con-
centrations were determined by the Amplicor monitor
test (Roche, Basel, Switzerland) or by the NASBA
method (Organon Teknika, Turnhout, Belgium),
Fig. 1. Correlation between the plasma HIV-1 RNA concentration detected by the Amplicor assay and the enhancement/
neutralization index (E/NI) measured in MT-4 cell cultures infected with mixtures of HIV-1IIIB, 1 : 64 dilutions of heat-treated
serum samples with (A) or without (B) pooled serum from HIV seronegative subjects as complement source in 98 HIV-infected
subjects. Values above the dashed line indicate enhancement whereas those below the dotted line indicate neutralization.
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whereas in the other two studies only the Amplicor




antibody-dependent enhancement and HIV-1
RNA concentrations
C-ADE and HIV-1 RNA concentrations were deter-
mined in the serum and plasma samples, respectively,
taken at the same time from 98 patients. A strong posi-
tive correlation was found between viral load and
E/NI measured in MT-4 cell cultures infected with
complement-containing mixtures (Fig. 1A), whereas in
cultures with no complement added a much weaker
but still significant positive correlation was obtained 
(Fig. 1B). A similar correlation was found between
viral load measured with the NASBA method and
E/NI values (R = 0.627, P < 0.0001, and R = 0.207, P
= 0.041, respectively, data not shown).
When E/NI values measured in sera from patients with
detectable and undetectable HIV-1 RNA were com-
pared, E/NI values measured in cultures infected in the
presence of complement were significantly (P < 0.0001,
Mann–Whitney test) higher in the sera from patients
with detectable [1.75 (1.24–2.21), median (25–75th
percentile)] than in those with undetectable viral load
[1.02 (0.46–1.43)]. In contrast, there were no signifi-
cant (P = 0.109) differences between the same groups
in E/NI values measured in cultures infected without
complement [0.69 (0.57–0.81) and 0.60 (0.29–0.86),
respectively].
Next, the patients were divided according to the E/NI
values measured in cultures infected in the presence
and absence of complement (Table 1). No HIV-1
RNA could be detected in plasma samples of patients
whose sera neutralized HIV-1 not only in the absence
but also in the presence of complement. Viral load was
markedly higher in patients whose serum samples neu-
tralized HIV-1 only in the absence of complement,
whereas the highest HIV-1 RNA concentrations were
measured in the group of patients whose sera did not
neutralize HIV infection even in the presence of com-
plement. According to the Kruskal–Wallis test, there
was a highly significant (P = 0.0014) difference among
the three groups of the patients.
In the 98 patients tested, CD4 cell counts inversely
correlated to the E/NI values measured in cultures
infected in the presence of complement (Fig. 2). In
addition, E/NI values measured in the presence of
complement were significantly (P = 0.02) higher in the
AIDS patients than in patients in a less advanced (CDC
stage III or IVA) stage of HIV disease (data not shown).
In control experiments, serum samples from 48 HIV-
negative persons were tested. No neutralizing or
enhancing activities were found either in the presence
or absence of complement in these sera (data not
shown).
Early appearance of complement-mediated
antibody-dependent enhancement after HIV
infection
The presence of C-ADE was studied in samples of four
different seroconversion panels. MT-4 cell cultures
were infected with mixtures of the virus and serum
with complement added (Fig. 3). HIV antibody titres
measured by the sensitive Abbott HIV 1/2 kit and the
amounts of HIV antigen measured by the Abbott kit are
also indicated; the extent of these parameters are given
as the quotient of the sample optical density (OD) and
cut-off OD. In cultures infected with virus–serum–
Table 1. Correlation of virus neutralization in the presence or absence of complement with plasma HIV-1 RNA (Amplicor)
HIV-1 RNA, copies/ml, median 
No. of patients tested (25–75th percentile)
E/NI < 0.5 (neutralization) both in the presence and absence of complement 12 200 (200–200)
E/NI < 0.5 (neutralization) only in the absence of complement 17 19 000 (200–25 000)
No neutralization in either the absence or presence of complement 69 43 000 (200–226 000)
Kruskal–Wallis test (P value) 0.0014
E/NI, enhancement/neutralization index.
Fig. 2. Correlation of the enhancement/neutralization index
(E/NI) values measured in cultures infected in the presence
of complement with the CD4 cell counts in 98 HIV-infect-
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complement mixtures, concomitant or just before (pan-
els D and P) seroconversion detected with the Abbott
antibody kit, at approximately day 35–40, a marked rise
in the E/NI values was observed in all the four panels
tested. Furthermore, this correlated, in general, with an
increase in p24 antigenaemia and, for the three patients
tested, it correlated in general with the appearance of
HIV-1 RNA. (Fig. 3). By contrast, in the cultures
infected with virus–serum mixtures without comple-
ment an E/NI value of 1 or less than one was observed
at all time-points tested (data not shown).
Increase of both complement-mediated
antibody-dependent enhancement and HIV-1
RNA during a longitudinal investigation in
advanced stage HIV patients
E/NI values and HIV-1 RNA levels were longitudi-
nally tested in 18 patients. The data obtained at the
beginning and the end of the 17 month (median)
observation period are shown in Fig. 4. Both the E/NI
values and the viral load markedly increased during the
follow-up period, and the differences between the initial
and the end values were highly significant. There were
no differences in the changes of either C-ADE of HIV-1
RNA values between the treated and untreated 
subgroups. Both parameters significantly (P < 0.05)
increased in both groups during the observation period.
Discussion
In the present study levels of an index (E/NI) value
reflecting the ratio of antibodies enhancing and neutral-
izing HIV-1 infection in vitro were found to be strongly
associated in almost 100 patients with the plasma HIV-1
RNA levels, the best known predictor of progression
of HIV-1 disease. This correlation indicates a strong
association between the balance of C-ADE mediating
and neutralizing antibodies on one hand and viral load
on the other.
Fig. 3. Temporal changes of enhancement/neutralization index (E/NI) values, HIV-1 antigen, antibody and RNA levels in four dif-
ferent HIV-1 seroconversion panels. Enhancement/neutralization index values in MT-4 cell cultures infected with mixtures of
HIV-1IIIB, 1 : 64 dilutions of recalcified and heat-treated samples and supplemented with pooled serum from HIV-seronegative
subjects as complement source (V– –– – –– –V) are shown on the left y-axis. HIV antibody titres measured by the Abbott HIV
1/2 kit (l– – – – – –l), the level of p24 antigen determined by the Abbott antigen test (v________v) expressed in both cases
in sample OD/cut-off OD (s/co) values are shown on the right y-axis. HIV RNA levels (+, detectable; –, undetectable; n.d., not
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The association between viral load and C-ADE can be
explained in two different ways. First, it seems probable
that changes in levels of HIV-1 RNA are driven by C-
ADE activity. Sullivan et al. [31] demonstrated specific
antibodies and complement fragments on virus particles
isolated from the plasma of HIV-infected individuals.
This observation indicates that, in vivo, complement is
activated by HIV-1 in plasma, which may lead to the
opsonization and lysis of the virions. On the basis of
this study and our previous findings [27,29] we
hypothesize that C-ADE-mediating antibodies increase
the amounts of HIV-1 particles not only in vitro but
also in vivo. They may inhibit complement-mediated
elimination of the free virus particles or may increase
virus production of the short-lived CD4 cells that pro-
duce 95–99% of the plasma virus, or both. The
hypothesis is supported by the findings of this study. If
our present findings are reproducible in the early stage
of HIV disease, it can be assumed that C-ADE may be
one of the factors that determines the set-point of viral
load and consequently the progression of HIV disease.
Second, on the other hand, it cannot be excluded that
the high HIV antigen load associated with the high
viral burden induces increased, dose-dependent synthe-
sis of C-ADE-mediating antibodies. However, no posi-
tive correlation between viral load and neutralizing
antibodies or the total amounts of enzyme-linked
immunosorbent assay (ELISA)-reactive HIV antibodies
has been described so far.
We found that complement-mediated infection
enhancing activity appeared early and increaseed as a
function of time after HIV infection. The early 
appearance of C-ADE in HIV infection is in complete
accordance with the findings of Montefiori et al. [32],
who found C-ADE activity in the sera obtained during
acute primary infection in macaques inoculated with
simian immunodeficiency virus (SIV)mac251. This
activity emerged before neutralizing antibodies and
coincided with the initial peak and decline of plasma
antigenaemia. Because the trapping of HIV on the
FDC in the germinal centres of lymph nodes occurs
very early after seroconversion, and the attachment of
HIV immune complexes to FDC is a complement-
mediated process [33], it is reasonable to suppose that
C-ADE-mediating antibodies present in HIV-infected
persons at the same time may be one of the decisive
factors of the HIV trapping in lymph nodes.
In the longitudinal study, both the E/NI values and
viral load were found to increase markedly during a 1.5
year long follow-up period. In the cross-sectional
study, a significant negative correlation was found
between C-ADE and CD4 cell counts. E/NI values
measured in the presence of complement were signifi-
cantly higher in the AIDS patients than in patients in a
less advanced (CDC stage III or IVA) stage of HIV 
disease. These observations in accordance with our pre-
vious results [29] indicate that the magnitude of
enhancement measured in complement-containing
serum samples from HIV-1-infected individuals corre-
lates with immunosuppression and disease. It seems that
the balance between the neutralizing and enhancing
antibodies is switched towards the dominance of
enhancing antibodies in the late symptomatic stage of
HIV infection, and this switch may be one of the dri-
ving forces of the increase of viral load preceding clini-
cal progression.
The main target of the C-ADE-mediating antibodies is
the so-called immunodominant epitope of gp41 (see
below). Therefore if the assumption on the switch in
Fig. 4. Initial and end measurement in 18 HIV patients of the enhancement/neutralization index (E/NI) (A) measured in MT-4
cell cultures infected with mixtures of HIV-1IIIB, 1 : 64 dilutions of heat-treated serum samples and pooled serum from 
HIV-seronegative subjects as complement source and of plasma HIV-1 RNA concentrations with the Amplicor test (B) during a
17 month observation period. Significance between the two groups: for A: P = 0.0017, for B: P< 0.0001. Median values are
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humoral immunity is correct, an increase in the anti-
gp41 antibodies is expected in the late stage of HIV
disease. An increase in the titres and affinity of the 
anti-gp41 antibodies in patients with symptomatic HIV
disease compared with the asymptomatic individuals
was reported by two groups [34,35].
Our present novel findings, together with those
reported previously by our group and others [27–29],
thus indicate that C-ADE may markedly influence the
natural course of HIV disease. This assumption is in
disagreement with the results of Montefiori et al. [36],
who did not find any correlation between C-ADE-
mediating antibodies and clinical progression. This dis-
cordance is most probably due to methodological
differences: Montefiori et al. [36] used a much lower
complement concentration, much higher input
virus/cell ratio and other target cells (MT-2 versus
MT-4) for culturing the virus.
The findings described in this and previous papers
[27–29] were obtained in an apparently non-physiolog-
ical system. The target cell, MT-4, like MT-2 used in
other studies [23–25,36] is a human T cell lymphoma
virus type I-infected cell-line [37] and HIV-1IIIB is a
laboratory, X4 strain passaged many times through T
cell lines. Recent studies, however, indicate that the
system is much closer to the in-vivo situations than it
appears to be. Nielsen et al. [38] demonstrated that C-
ADE occurs in vitro in peripheral blood mononuclear
cells, although it was not as dramatic as that detected in
cell lines. The presence of CR2 critical for C-ADE was
described in 10–50% of the circulating T cells [39,40],
indicating that the use of a CR2-carrying target cell for
measuring complement-related humoral factors influ-
encing HIV growth is reasonable. Recent studies of
Spear et al. [41] indicate that B cells play an important
role in the enhancement of the infectivity of HIV-1 for
T cells by antibody and complement.
An additional important question is why the measure-
ments performed with one single T cell-adapted strain,
HIV-1IIIB, strongly correlates with the viral load and
clinical progression of patients most probably infected
with several other R5 and X4 HIV-1 strains. Recent
elegant studies of Mitchell et al. [42] and earlier obser-
vations of Robinson and colleagues [43,44] help to
resolve this apparent paradox. According to these
investigations, the primary antigenic domains responsi-
ble for the C-ADE of HIV and SIV resides in the prin-
cipal immunodominant sequence of gp41. This is a
conserved sequence which, in accordance with the site-
directed mutagenesis experiments of Mitchell et al. [42],
is critical for the gp120–gp41 interaction. According to
their model, the binding site for enhancing antibodies
on the primary association site with gp41 is surrounded
by amino-linked oligosaccharides, which are probable
sites for the covalent attachment of the C3dg peptide of
C3, the physiological ligand of the CR2 receptor. The
binding site for enhancing antibodies on gp41 is easily
accessible after the release of gp120 from gp41 or after
a conformational change in gp120 after association with
CD4 cells and co-receptors [43].
In a similar way to the broadly reacting enhancing anti-
bodies, we could also detect broadly cross-reacting
neutralizing antibodies, which also seem to have prog-
nostic significance [7,45]. A distinguishing feature of
sera from long-term non-progressors is their higher
average titre of neutralizing antibodies to HIV-1 strains
IIIB and MN [46], and sera from long-term non-
progressors neutralize heterologous primary isolates
more effectively than do sera from progressors [45].
The development of broadly cross-reactive neutralizing
antibodies in patients might be explained by responses
against highly conserved epitopes [47] or by multiple
responses to isolate-specific epitopes that accumulated
over time [48]. The potential benefit of antibodies that
neutralize heterologous primary isolates has been
described [12].
Our present observations may have two implications
for HIV vaccine development. First, it seems that esti-
mation of HIV and SIV [32] neutralization and
enhancement by using complement and complement-
receptor carrying target cells correlates better to the
natural progression of HIV infection than any other
method applied for measuring HIV humoral immunity.
Therefore, it would be important to study if measure-
ments by this or a similar procedure can be used as a
correlate of HIV immune protection in animal experi-
ments and in trials of candidate AIDS vaccines. Second,
enhancing antibodies were found to develop after
active and passive immunization against several virus
infections, including retroviruses such as equine infec-
tious anaemia virus [reviewed in Ref. 42]. Similar find-
ings were obtained in SIV-immunized rhesus macaques
and in volunteers vaccinated with a HIV-1 gp160 
candidate vaccine [49–51]. Therefore, it is prudent to
consider the potential for the development of enhanc-
ing antibodies in all vaccine preparations and trials
[24,42,52].
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